Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Dec 2015

van den Brom Rob R H, Mäkelburg Anja B U, Schröder Carolien P, de Vries Elisabeth G E, Hospers Geke A P

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Fibrin Fibrinogen Degradation Products
Share to Fibrinogen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to L-Lactate Dehydrogenase

Share to Platelet Count

Share to S100 Calcium Binding Protein beta Subunit

Share to Tumor Burden

Share to Vemurafenib

Source

Identifiers

PMID: 24778390
DOI: 10.1200/JCO.2013.51.4471

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.PMID 24778390Read ↗

FDA approves vemurafenib for treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.Semantic proximity Read ↗

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Vemurafenib therapy for stage IV melanoma with V600G-mutation.Semantic proximity Read ↗

Vemurafenib. Value unclear in metastatic melanoma.Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.Semantic proximity Read ↗

Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.Semantic proximity Read ↗

Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.Semantic proximity Read ↗

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.